The Coalition for Epidemic Preparedness Innovations (CEPI) is collaborating with Serum Institute of India (SII) to boost pandemic response preparedness for Disease X, an unknown pathogen with pandemic potential, CEPI said.

A global partnership focused on developing vaccines, CEPI said the collaboration would use “a baculovirus vaccine platform to target H5N1 bird flu as a prototype for a potential Disease X”. Baculovirus-based vaccines use a harmless insect virus that has been genetically modified to produce an antigen of a given virus, the note said.

With CEPI funding of up to $16.4 million, “SII will use its validated baculovirus-based platform to produce and compare two H5 antigens for a recombinant protein vaccine: a wild-type and an AI-optimised, broad-spectrum H5 antigen designed b

See Full Page